PCN77 Cost-effectiveness analysis of adjuvant FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for resected pancreatic cancer in the United States: based on PRODIGE and APACT trial
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI